Objective: This study aims to construct a prognostic risk assessment model (PRAM) for non-small cell lung cancer (NSCLC) using radiomics and miRNA-10b expression. Patients and Methods: This study included 30 participants who underwent surgery or chemotherapy, and patient data were collected and analyzed. miRNA-10b mRNA in peripheral blood mononuclear cells was detected using RT-PCR. Tumor area was assessed by CT scan before and after treatment. The model was validated using internal and external data (using fivefold cross-validation) to ensure stability. Results: Posttreatment miRNA-10b mRNA levels were significantly downregulated compared with pretreatment levels. The integration of radiomics and miRNA-10b expression provided a robust prognostic tool, effectively distinguishing between favorable and poor outcomes. Conclusions: The combination of radiomics and miRNA-10b expression levels can be used to establish a reliable PRAM for NSCLC, enhancing prognostic accuracy and aiding in personalized treatment strategies. This dual-modality approach represents a significant advancement in the prognostic evaluation of NSCLC.
AsadiradA.KhodadadiA.TalaiezadehA., Shohan, M., Rashno, M., & Joudaki, N. (2022). Evaluation of miRNA-21-5p and miRNA-10b-5p levels in serum-derived exosomes of breast cancer patients in different grades. Molecular and Cellular Probes, 64(8), 101831. https://doi.org/10.1016/j.mcp.2022.101831
2.
CaoJ.YuanP.WangY., Xu, J., Yuan, X., Wang, Z., Lv, W., & Hu, J. (2018). Survival rates after lobectomy, segmentectomy, and wedge resection for non-small cell lung cancer. The Annals of Thoracic Surgery, 105(5), 1483–1491. https://doi.org/10.1016/j.athoracsur.2018.01.032
3.
ChetanM. R.GleesonF. V. (2021). Radiomics in predicting treatment response in non-small-cell lung cancer: Current status, challenges and future perspectives. European Radiology, 31(2), 1049–1058. https://doi.org/10.1007/s00330-020-07141-9
4.
ElgeshyK. M.Abdel WahabA. H. A. (2022). The role, significance, and association of microRNA-10a/b in physiology of cancer. MicroRNA (Shariqah, United Arab Emirates), 11(2), 118–138. https://doi.org/10.2174/2211536611666220523104408
5.
GriesingerF.KorolE. E.KayaniyilS., Varol, N., Ebner, T., & Goring, S. M. (2019). Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer (Amsterdam, Netherlands), 135, 196–204. https://doi.org/10.1016/j.lungcan.2019.07.010
6.
HigginsK. A.PuriS.GrayJ. E. (2022). Systemic and radiation therapy approaches for locally advanced non-small-cell lung cancer. Journal of Clinical Oncology, 40(6), 576–585. https://doi.org/10.1200/JCO.21.01707
7.
HirschF. R.ScagliottiG. V.MulshineJ. L., Kwon, R., Curran, W. J., Jr., Wu, Y. L., & Paz-Ares, L. (2017). Lung cancer: Current therapies and new targeted treatments. Lancet (London, England), 389(10066), 299–311. https://doi.org/10.1016/S0140-6736(16)30958-8
HoriuchiM.OguriT.KagawaY., Ohkubo, H., Takemura, M., Ito, Y., & Niimi, A. (2022). Differences in the therapeutic effect of chemotherapy regimens for concurrent chemoradiotherapy of locally advanced non-small cell lung cancer. Anticancer Research, 42(2), 1073–1079. https://doi.org/10.21873/anticanres.15569
10.
HuangY.LiuZ.HeL., Chen, X., Pan, D., Ma, Z., Liang, C., Tian, J., & Liang, C. (2016). Radiomics signature: A potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. Radiology, 281(3), 947–957. https://doi.org/10.1148/radiol.2016152234
11.
IndoriaD.SinghJ.SinghY. P., Bura, K., & Prabhishek, S. (2023). Utilizing sentiment analysis for assessing suicidal risk in personal journal entries. In Proceedings of the 2023 3rd international conference on innovative sustainable computational technologies (CISCT), F. IEEE.
12.
JiangH.LiuJ.ChenY., Ma, C., Li, B., & Hao, T. (2016). Up-regulation of mir-10b predicate advanced clinicopathological features and liver metastasis in colorectal cancer. Cancer Medicine, 5(10), 2932–2941. https://doi.org/10.1002/cam4.789
13.
KapoorV.MittalA.GargS., Bura, K., & Prabhishek, S. (2023). Lung cancer detection using VGG16 and CNN. In Proceedings of the 2023 IEEE world conference on applied intelligence and computing (AIC), F. IEEE.
14.
KumarS.SinghJ.RaviV., Alanoud, M., Manoj, D., & Indrajeet, G. (2024). Deep learning and MRI biomarkers for precise lung cancer cell detection and diagnosis. The Open Bioinformatics Journal, 17(1), 29–41. https://doi.org/10.2174/0118750362335415240909061539
15.
LiuY.LiM.ZhangG., & Pang, Z. (2013). MicroRNA-10b overexpression promotes non-small cell lung cancer cell proliferation and invasion. European Journal of Medical Research, 18(1), 41. https://doi.org/10.1186/2047-783X-18-41
16.
MayerhoeferM. E.MaterkaA.LangsG., Piotr, N., Peter, G., & Gary, C. (2020). Introduction to radiomics. Journal of Nuclear Medicine, 61(4), 488–495. https://doi.org/10.2967/jnumed.118.222893
17.
MillerM.HannaN. (2021). Advances in systemic therapy for non-small cell lung cancer. BMJ (Clinical Research Ed), 375(9), n2363. https://doi.org/10.1136/bmj.n2363
RumgayH.ArnoldM.FerlayJ., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022). Global burden of primary liver cancer in 2020 and predictions to 2040. Journal of Hepatology, 77(6), 1598–1606. https://doi.org/10.1016/j.jhep.2022.08.021
20.
SaliminejadK.Khorram KhorshidH. R.Soleymani FardS., & Ghaffari, SH. (2019). An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. Journal of Cellular Physiology, 234(5), 5451–5465. https://doi.org/10.1002/jcp.27486
21.
SchabathM. B.CoteM. L. (2019). Cancer progress and priorities: Lung cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 28(10), 1563–1579. https://doi.org/10.1158/1055-9965.EPI-19-0221
22.
ShiL.HeY.YuanZ., Benedict, S., Valicenti, R., Qiu, J., & Rong, Y. (2018). Radiomics for response and outcome assessment for non-small cell lung cancer. Technology in Cancer Research & Treatment, 17(1), 1533033818782788. https://doi.org/10.1177/1533033818782788
TongH.SunJ.FangJ., Zhang, M., Liu, H., Xia, R., Zhou, W., Liu, K., & Chen, X. (2022). A machine learning model based on PET/CT radiomics and clinical characteristics predicts tumor immune profiles in non-small cell lung cancer: A retrospective multicohort study. Frontiers in Immunology, 13(4), 859323. https://doi.org/10.3389/fimmu.2022.859323
25.
WangT.SheY.YangY., Zhao, M., Sun, X., Xie, D., & Chen, C. (2022). Radiomics for survival risk stratification of clinical and pathologic stage IA pure-solid non-small cell lung cancer. Radiology, 302(2), 425–434. https://doi.org/10.1148/radiol.2021210109
26.
WangX.DuanH.LiX., Ye, X., Huang, G., & Nie, S. (2020). A prognostic analysis method for non-small cell lung cancer based on the computed tomography radiomics. Physics in Medicine and Biology, 65(4), 045006. https://doi.org/10.1088/1361-6560/ab6e51
27.
WonnacottA.DenbyL.CowardR. J. M., Fraser, D. J., & Bowen, T. (2022). MicroRNAs and their delivery in diabetic fibrosis. Advanced Drug Delivery Reviews, 182(3), 114045. https://doi.org/10.1016/j.addr.2021.114045
28.
WuK.HuY.YanK., Zhu, D., Liu, D., & Zhao, S. (2020). microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer. Journal of Cellular Physiology, 235(2), 1247–1258. https://doi.org/10.1002/jcp.29040
29.
XiaoP. P.WanQ. Q.LiaoT., Tu, J. Y., Zhang, G. J., & Sun, Z. Y. (2021). Peptide nucleic acid-functionalized nanochannel biosensor for the highly sensitive detection of tumor exosomal microRNA. Analytical Chemistry, 93(31), 10966–10973. https://doi.org/10.1021/acs.analchem.1c01898
30.
YangY. L.XuL. P.ZhuoF. L., & Wang, T. Y. (2015). Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine, 36(9), 7069–7075. https://doi.org/10.1007/s13277-015-3366-6
